We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Maine health officials have delayed implementing the state’s groundbreaking prescription drug discount program — which also faces ongoing legal challenges from PhRMA — as they consider how the state drug plan jibes with the new federal drug benefit.
Rather than focusing solely on product and brand management, drugmakers are turning to patient-oriented efforts such as Rx compliance and disease management programs to increase revenue, according to a report from Cutting Edge Information.
Wholesalers and distributors who do not comply with new supply chain requirements issued by Pfizer will be left out in the cold when it comes to trafficking the drug giant’s products, the firm announced late December.
Communications that Amylin Pharmaceuticals made about its diabetes drug candidate Symlin will fall under the scrutiny of the Securities and Exchange Commission (SEC) under an informal inquiry, the company announced last month.
An FTC ruling in December that agreements between Schering-Plough and a pair of generic competitors were anticompetitive sends a message to pharma firms contemplating similar deals, with some experts saying such agreements may no longer be in favor in the industry.